Endometrioma Sclerotherapy and Ovarian Preservation (NCT06775769) | Clinical Trial Compass
RecruitingNot Applicable
Endometrioma Sclerotherapy and Ovarian Preservation
United Kingdom60 participantsStarted 2025-02-21
Plain-language summary
A randomised controlled trial assessing ovarian reserve after laparoscopic ethanol sclerotherapy of ovarian endometrioma compared to standard treatment of surgical excision of endometrioma.
Secondary outcomes will include endometrioma recurrence, symptomatology and inflammatory environment.
Who can participate
Age range18 Years – 45 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Female (XX genotype, assigned female at birth)
* Age 18-40
* Finding of suspected uni- or bi-lateral ovarian endometrioma(ta) of ≥ 2cm on TVUSS and/or pelvic MRI scan (TVUSS, a uni- or multi-locular ovarian cystic lesion with low level echoes and diffuse homogeneous ground glass appearance; MRI any of, ovarian lesion hyperintense T1 without loss of signal on T1 fat-suppressed images, hypointense T2 exhibiting shading sign and/or T2 dark spot sign, variable restricted diffusion on DWI)
* Appropriate to be listed for laparoscopic excision of endometrioma (Endometrioma ≥2cm, pain symptoms attributable to endometriosis where medical management is unsuccessful or unacceptable to the patient, to facilitate ART)
Exclusion Criteria:
* Postmenopausal status
* Suspicion of malignancy
* Unable to undergo TVUSS
* Declines to take part in the study
* Unable to understand verbal or written information in English
* Lack of capacity to consent at the point of recruitment
* Known safeguarding issues
What they're measuring
1
Ovarian Reserve
Timeframe: 24 months
Trial details
NCT IDNCT06775769
SponsorChelsea and Westminster NHS Foundation Trust